Renalytix Plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more
Renalytix Plc (RNLXY) - Net Assets
Latest net assets as of December 2024: $-1.37 Million USD
Based on the latest financial reports, Renalytix Plc (RNLXY) has net assets worth $-1.37 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.44 Million) and total liabilities ($12.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.37 Million |
| % of Total Assets | -11.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 66.2 |
Renalytix Plc - Net Assets Trend (2021–2025)
This chart illustrates how Renalytix Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Renalytix Plc (2021–2025)
The table below shows the annual net assets of Renalytix Plc from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $-7.00 Million | +10.87% |
| 2024-06-30 | $-7.85 Million | -212.73% |
| 2023-06-30 | $6.97 Million | -77.24% |
| 2022-06-30 | $30.61 Million | -67.82% |
| 2021-06-30 | $95.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Renalytix Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4478.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $158.10 Million | % |
| Total Equity | $-7.00 Million | 100.00% |
Renalytix Plc Competitors by Market Cap
The table below lists competitors of Renalytix Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kudelski S.A.
LSE:0QNQ
|
$81.42 Million |
|
Rani Therapeutics Holdings Inc
NASDAQ:RANI
|
$81.42 Million |
|
Phoenix Asia Holdings Limited Ordinary Shares
NASDAQ:PHOE
|
$81.48 Million |
|
Nivika Fastigheter AB Series B
ST:NIVI-B
|
$81.49 Million |
|
GENOR BIOPHARMA DL-00002
F:67N0
|
$81.40 Million |
|
OPTGF
PINK:OPTGF
|
$81.36 Million |
|
Unggul Indah Cahaya Tbk
JK:UNIC
|
$81.35 Million |
|
Keding Enterprises Co Ltd
TW:6655
|
$81.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Renalytix Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -7,854,000 to -7,000,000, a change of 854,000.
- Net loss of 20,400,000 reduced equity.
- New share issuances of 19,500,000 increased equity.
- Other factors increased equity by 1,754,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.40 Million | -291.43% |
| Share Issuances | $19.50 Million | +278.57% |
| Other Changes | $1.75 Million | +25.06% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Renalytix Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | $1.32 | $0.23 | x |
| 2022-06-30 | $0.41 | $0.23 | x |
| 2023-06-30 | $0.07 | $0.23 | x |
| 2024-06-30 | $-0.05 | $0.23 | x |
| 2025-06-30 | $-0.02 | $0.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Renalytix Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -680.00%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-167.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -32.61% | -2079.81% | 0.01x | 1.08x | $-40.52 Million |
| 2022 | -147.93% | -1524.44% | 0.06x | 1.64x | $-48.34 Million |
| 2023 | -654.61% | -1340.20% | 0.11x | 4.40x | $-46.30 Million |
| 2024 | 0.00% | -1978.26% | 0.29x | 0.00x | $-44.71 Million |
| 2025 | 0.00% | -680.00% | 0.49x | 0.00x | $-19.70 Million |
Industry Comparison
This section compares Renalytix Plc's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Renalytix Plc (RNLXY) | $-1.37 Million | -32.61% | N/A | $81.41 Million |
| Abcam plc (ABCZF) | $726.90 Million | -1.17% | 0.45x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $11.42 Million | 85.41% | 3.81x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.25 Million |
| Adamas Trust, Inc. (ADAMG) | $2.43 Billion | 7.94% | 1.33x | $2.09 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $33.92 Million | -162.39% | 2.67x | $10.06 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $5.32 Million | -457.58% | 45.29x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $4.04 Billion | 10.04% | 0.29x | $112.87K |
| Alvotech Warrant (ALVOW) | $-564.42 Million | 0.00% | 0.00x | $35.01 Million |